BRPI0711599A8 - Métodos para coleta e de uso de células-tronco de sangue de cordão umbilical de placenta - Google Patents

Métodos para coleta e de uso de células-tronco de sangue de cordão umbilical de placenta

Info

Publication number
BRPI0711599A8
BRPI0711599A8 BRPI0711599A BRPI0711599A BRPI0711599A8 BR PI0711599 A8 BRPI0711599 A8 BR PI0711599A8 BR PI0711599 A BRPI0711599 A BR PI0711599A BR PI0711599 A BRPI0711599 A BR PI0711599A BR PI0711599 A8 BRPI0711599 A8 BR PI0711599A8
Authority
BR
Brazil
Prior art keywords
placenta
stem cells
isolated
umbilical cord
perfusion
Prior art date
Application number
BRPI0711599A
Other languages
English (en)
Inventor
Takebe Naoko
Original Assignee
Takebe Naoko
Hli Cellular Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takebe Naoko, Hli Cellular Therapeutics Llc filed Critical Takebe Naoko
Publication of BRPI0711599A2 publication Critical patent/BRPI0711599A2/pt
Publication of BRPI0711599A8 publication Critical patent/BRPI0711599A8/pt
Publication of BRPI0711599B1 publication Critical patent/BRPI0711599B1/pt
Publication of BRPI0711599B8 publication Critical patent/BRPI0711599B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dentistry (AREA)

Abstract

MÉTODOS PARA COLETA E DE USO DE CÉLULAS-TRONCO DE SANGUE DE CORDÃO UMBILICAL DE PLACENTA. É descrito um método inovador de coleta de células-tronco de sangue de cordão umbilical a partir de uma placenta de mamífero isolada, não exsanguinada ou parcialmente exsanguinada, por perfusão placentária. A perfusão placentária pode incluir a perfusão da placenta isolada com um escoamento pulsátil de solução de perfusão, por exemplo, usando uma bomba ou dispositivo pulsátil ou peristáltico. As células-tronco podem, então, ser isoladas a partir do perfusato. A solução de perfusão pode incluir um anticoagulante. A placenta de mamífero isolada não necessita ser tratada com um anticoagulante antes da perfusão. A placenta isolada pode ser livre de um anticoagulante antes da perfusão.
BRPI0711599A 2006-05-11 2007-05-11 métodos para coleta e de uso de células-tronco de sangue de cordão umbilical de placenta BRPI0711599B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79973406P 2006-05-11 2006-05-11
US60/799,734 2006-05-11
PCT/US2007/011359 WO2007133665A2 (en) 2006-05-11 2007-05-11 Methods for collecting and using placenta cord blood stem cells

Publications (4)

Publication Number Publication Date
BRPI0711599A2 BRPI0711599A2 (pt) 2011-11-16
BRPI0711599A8 true BRPI0711599A8 (pt) 2017-04-04
BRPI0711599B1 BRPI0711599B1 (pt) 2021-03-02
BRPI0711599B8 BRPI0711599B8 (pt) 2021-07-27

Family

ID=38694487

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711599A BRPI0711599B8 (pt) 2006-05-11 2007-05-11 métodos para coleta e de uso de células-tronco de sangue de cordão umbilical de placenta

Country Status (14)

Country Link
US (4) US8329468B2 (pt)
EP (4) EP2023717B1 (pt)
JP (1) JP5260499B2 (pt)
KR (1) KR101514078B1 (pt)
CN (2) CN101483998A (pt)
BR (1) BRPI0711599B8 (pt)
CA (3) CA3103505C (pt)
ES (1) ES2581738T3 (pt)
IL (1) IL195241A (pt)
MX (1) MX2008014426A (pt)
MY (1) MY157763A (pt)
SG (3) SG171669A1 (pt)
WO (1) WO2007133665A2 (pt)
ZA (1) ZA200809770B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
US9944900B2 (en) * 2006-01-18 2018-04-17 Hemacell Perfusion Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
US8673547B2 (en) * 2007-03-08 2014-03-18 Hemacell Perfusion, Inc. Method for isolation of afterbirth derived cells
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2010057110A1 (en) * 2008-11-14 2010-05-20 University Of Louisville Research Foundation, Inc. Methods and compositions for long term hematopoietic repopulation
AU2009316541B2 (en) 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
US20130323708A1 (en) * 2009-07-01 2013-12-05 Massachusetts Institute Of Technology Isolated adult cells, artificial organs, rehabilitated organs, research tools, organ encasements, organ perfusion systems, and methods for preparing and utilizing the same
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
US10575515B2 (en) 2010-05-04 2020-03-03 The General Hospital Corporation Methods and compositions for preserving tissues and organs
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CN102757935A (zh) * 2011-04-29 2012-10-31 北京汉氏联合生物技术有限公司 一种从胎盘绒毛膜组织中提取造血干细胞的方法及造血干细胞库的构建方法
JP6104896B2 (ja) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション 胎盤幹細胞を使用する疼痛の治療
US10190092B2 (en) 2011-08-11 2019-01-29 Robert A. Dracker Procurement of placental stem cells
WO2013049670A1 (en) * 2011-09-28 2013-04-04 Epic Sciences, Inc. Method for optimizing the collection of rare cells in blood
KR20220044384A (ko) * 2013-10-03 2022-04-07 안트로제네시스 코포레이션 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료
CN105916521A (zh) * 2013-11-15 2016-08-31 人类起源公司 包含人胎盘灌注液细胞、其亚群的组合物及其用途
CN103756965B (zh) * 2014-01-27 2016-04-06 山东省齐鲁干细胞工程有限公司 一种从胎盘中灌洗造血干细胞的方法
CN103789262A (zh) * 2014-02-17 2014-05-14 宁波普莱森特生物科技有限公司 一种临床应用级胎盘造血干细胞的制备方法及保存方法
US10918102B2 (en) 2014-03-13 2021-02-16 The General Hospital Corporation Devices and methods to improve and assess viability of human livers
FR3035407B1 (fr) 2015-04-23 2022-06-17 Francais Du Sang Ets Procede de conservation de cellules, tissus ou organes en hypothermie
CA3032160C (en) 2016-08-24 2024-05-28 Arthrex, Inc. Tissue hybrid for use in repairing, reconstructing or regenerating musculoskeletal degenerative processes or injuries
EP3638019A4 (en) 2017-06-14 2020-08-26 The General Hospital Corporation VERY LOW TEMPERATURE CRYOPRESERVATION
CN108531454A (zh) * 2018-04-09 2018-09-14 孔五 脐带血再生粒子及组合物在治疗大脑退行性疾病中的用途
US12167729B2 (en) 2018-05-30 2024-12-17 The General Hospital Corporation Cryopreservation of tissues and organs
KR20210111244A (ko) * 2018-11-30 2021-09-10 셀룰래리티 인코포레이티드 태반-유래 동종이계 car-t 세포 및 이의 용도
US11511017B2 (en) 2019-03-12 2022-11-29 Arthrex, Inc. Ligament reconstruction

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425687A1 (en) 2000-10-27 2002-05-02 Cornell Research Foundation, Inc. Alteration of plant nitrate and oxalic acid concentration
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da) * 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en) * 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
KR101176146B1 (ko) * 2002-02-13 2012-08-22 안트로제네시스 코포레이션 산후 포유류 태반으로부터 유래한 배아-유사 줄기 세포와그 세포를 사용한 용도 및 치료방법
US7060494B2 (en) * 2002-04-09 2006-06-13 Reliance Life Sciences Pvt. Ltd. Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof
JP2005522215A (ja) * 2002-04-12 2005-07-28 セルジーン・コーポレーション 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2004071283A2 (en) * 2003-02-13 2004-08-26 Anthrogenesis Corporation Use of umbilical cord blood to treat individuals having a disease, disorder or condition
CN1548529A (zh) 2003-05-09 2004-11-24 中国人民解放军军事医学科学院基础医 一种人胎盘间充质干细胞的分离方法
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2005059152A1 (en) * 2003-12-18 2005-06-30 Cerestar Holding B.V. Oxidation of carbohydrates by means of peroxidases and nitroxy radicals
WO2006088867A2 (en) * 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
DK1957633T3 (en) * 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
PT2471904T (pt) * 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
KR100783711B1 (ko) 2006-01-06 2007-12-07 삼성전자주식회사 금속 화합물 및 이를 포함하는 유기 전계 발광 소자
US9944900B2 (en) * 2006-01-18 2018-04-17 Hemacell Perfusion Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells

Also Published As

Publication number Publication date
CA3103505A1 (en) 2007-11-22
BRPI0711599B8 (pt) 2021-07-27
US20130108591A1 (en) 2013-05-02
EP4094578A1 (en) 2022-11-30
ES2581738T3 (es) 2016-09-07
CN101483998A (zh) 2009-07-15
BRPI0711599B1 (pt) 2021-03-02
KR101514078B1 (ko) 2015-04-22
US9364585B2 (en) 2016-06-14
CA2652051C (en) 2015-12-08
US20090123437A1 (en) 2009-05-14
CA3103505C (en) 2023-07-04
EP2023717A2 (en) 2009-02-18
KR20090026158A (ko) 2009-03-11
JP2009536824A (ja) 2009-10-22
CN105087490A (zh) 2015-11-25
EP3603390B1 (en) 2023-12-20
SG191608A1 (en) 2013-07-31
US20200138872A1 (en) 2020-05-07
US10548926B2 (en) 2020-02-04
BRPI0711599A2 (pt) 2011-11-16
CA2909053A1 (en) 2007-11-22
EP2023717A4 (en) 2009-12-16
CA2909053C (en) 2021-02-09
WO2007133665A3 (en) 2008-12-18
CA2652051A1 (en) 2007-11-22
IL195241A (en) 2014-02-27
ZA200809770B (en) 2010-03-31
MY157763A (en) 2016-07-15
EP3603390A1 (en) 2020-02-05
MX2008014426A (es) 2009-02-18
US8329468B2 (en) 2012-12-11
SG10201804146XA (en) 2018-06-28
JP5260499B2 (ja) 2013-08-14
EP3114931A1 (en) 2017-01-11
EP2023717B1 (en) 2016-04-13
WO2007133665A2 (en) 2007-11-22
SG171669A1 (en) 2011-06-29
US20160220618A1 (en) 2016-08-04
IL195241A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
BRPI0711599A8 (pt) Métodos para coleta e de uso de células-tronco de sangue de cordão umbilical de placenta
RU2015154110A (ru) Содержащий трегалозу и декстран раствор для трансплантации клеток млекопитающих
WO2012074978A3 (en) Method of and apparatus for sampling, processing and collecting tissue and reinjecting the same into human patients
WO2010140150A3 (en) Arterial device, system and method
WO2015138832A1 (en) Devices and methods to improve and assess viability of human livers
MX2017002921A (es) Sistema de toma de muestras de sangre para mejorar el exito de la extraccion y reducir la hemolisis.
BR112015010555A2 (pt) método implementado por computador para a previsão de uma resposta imune após transplante, método para a seleção de uma célula ou preparação de tecido ou órgão para o transplante alogênico, método para a seleção e/ou triagem de material doador para transplante alogênico com incompatibilidades aceitáveis, e método para a previsão de resultado terapêutico de um transplante
Qiang et al. Human amniotic mesenchymal stem cells alleviate lung injury induced by ischemia and reperfusion after cardiopulmonary bypass in dogs
WO2012106367A3 (en) Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
WO2009137829A3 (en) Directed stem cell recruitment
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
Bral et al. Ex situ liver perfusion: Organ preservation into the future
CN202999168U (zh) 一种离体肾脏连续灌注保存装置
TWD168034S (zh) 凍結保存容器
BR112023017829A2 (pt) Composição para prevenir ou tratar uma infecção por um patógeno em um órgão, tecido e/ou cultura de células-tronco ex vivo antes do transplante, kit para prevenção ou tratamento de uma infecção por um patógeno em um órgão, tecido e/ou cultura de células-tronco ex vivo, sistema de perfusão configurado para manter um órgão ex vivo em um estado de funcionamento sob condições fisiológicas ou quase fisiológicas, método para tratamento ou prevenção de infecção por um patógeno em um órgão, tecido e/ou cultura de células-tronco ex vivo antes do transplante, e, uso de uma composição
BR112015022579A2 (pt) uso de shroom 3 em doença renal crônica e nefropatia crônica do aloenxerto
Fedulkina et al. Translational cellular immunotherapy for cadaveric kidney allograft in urological patients
RU2716574C1 (ru) Способ нерегламентированного замораживания клеток-предшественников периферической крови при температуре минус 80оС с раствором Гекмодиолит
Huang et al. Clinical Efficacy of Dual-Kidney Transplantation from Pediatric Donors to Adult Recipients
CN206261885U (zh) 一种便于人工肝操作的可旋转微量泵固定架
Zhang et al. Protective effect of N-acetylcysteine against pneumocyte apoptosis during ischemia/reperfusion injury of lung in rats
Wang et al. HEALTH-RELATED QUALITY OF LIFE AFTER LIVER TRANSPLANTATION AND ITS IMPACT FACTORS: EXPIERENCE FROM A CHINESE SINGLE CENTER: 610
RU2006100475A (ru) Способ трансплантации стволовых клеток при заболеваниях и поражениях печени
Salam et al. Umbilical cord blood banking and transplantation: a short review
Bykov et al. THE MATHEMATICAL MODELING ESTIMATION OF THE AORTIC VALVE STATE DURING MECHANICAL CIRCULATORY SUPPORT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2261 DE 06/05/2014.

B25A Requested transfer of rights approved

Owner name: HLI CELLULAR THERAPEUTICS, LLC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2827 DE 11-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.